7. December 2016

Stalosan F is able to reduce the need for antibiotics

by Jan Storgaard, Biochemist at Vilofoss

For many years Stalosan F has turned out to be a very useable agent for reducing the consumption of antibiotics and lowering the mortality in e.g. pig herds. In trials with Stalosan F the significant reduction in medicine use is recorded. For instance, this could be observed in a research project conducted by QAF Meat Industries Pty. Ltd in 2007. Two groups of piglets were part of the trial during a period of 26 days until weaning. In the trial the basic parameters in form of number of dead piglets and the need for treatment with antibiotics were investigated. See results in the table below.

 

Control (2045 liveborn)

Stalosan F (2034 liveborn)

Growth

0.215

0.225

Mortality

238

172

No. of treatments with antibiotics (Trisoprim-480)

622

375

 

In similar ways trials in Denmark and UK have shown reductions in consumption of antibiotics - some times as much as 75%.

 

Other trials with Stalosan F, conducted in cooperation with pig producers and affiliated slaughterhouses in Denmark, have shown a distinct decrease in the level of salmonella from 2-4 to the lowest level 1.  This was achieved by regular use of Stalosan F during a period of three months in average.

 

A published scientific study from University of Minnesota has demonstrated a 99% elimination of Lawsonia exposed to Stalosan F. This study supports several years of experience from Danish pig herds, where Stalosan F has been able to control the bacteria.

 

The biocide mechanism of action of Stalosan F makes no distinction between resistant and non-resistant bacteria, and thus e.g. no difference is seen in the effect towards staphylococcus aureus and MRSA or resistant versus non-resistant strains of E. coli and salmonella.

 

The above experiences combined with the general trial database of Stalosan F show a distinct picture of the fact that regular use of the product can reduce the consumption of antibiotics significantly – whether we are dealing with resistant bacteria or not.

jan storgaard
Jan Storgaard
Technical Development